Table 2.
Treatment recommendations based on BCR::ABL1 kinase domain mutation and responses to TKI therapy.
| Treatment | Contraindicated mutations |
|---|---|
| Dasatinib | T315I/A, F317L/V/I/C, or V299L |
| Nilotinib | T315I, Y253H, E255K/V, or F359V/C/I |
| Bosutinib | T315I, V299L, G250E, or F317L |
| Asciminib | A337T or P465S |
| Ponatinib | None |
| Contraindicated treatment | BCR::ABL1 mutations | Bosutinib [18] | Dasatinib [33] | Nilotinib [34] | Ponatinib [35] | ||
| MCyR | CCyR | MCyR | CCyR | MCyR | MCyR | ||
| Contraindication for bosutinib | G250E | 0/5 (0%) | 20/60 (33%) | 29/60 (48%) | 3/5 (60%) | 3/5 (60%) | 8/12 (67%) |
| Contraindication for bosutinib and dasatinib | F317L | 1/7 (14%) | 1/14 (7%) | 2/14 (14%) | - | - | 13/29 (45%) |
| V299L | 0/2 (0%) | - | - | - | - | 3/8 (38%) | |
| Contraindication for nilotinib | E255K | - | 6/16 (38%) | 9/16 (56%) | 0/7 (0%) | 3/7 (43%) | 8/13 (62%) |
| E255V | - | 4/11 (36%) | 4/11 (36%) | 1/4 (25%) | |||
| F359C | 1/2 (50%) | 3/5 (60%) | 3/5 (60%) | 0/11 (0%) | 1/11 (9%) | 1/7 (14%) | |
| F359V | 2/3 (67%) | 14/27 (52%) | 17/27 (63%) | 11/20 (55%) | |||
| F359I | 2/2 (100%) | 7/12 (58%) | 10/12 (83%) | - | - | 3/4 (75%) | |
| Y253H | 5/6 (83%) | 14/23 (61%) | 15/23 (65%) | 0/8 (0%) | 1/8 (13%) | 1/2 (50%) | |
Abbreviations: CCyR, complete cytogenetic response; MCyR, major cytogenetic response.